Innovative platinum derived anticancer agents - Risk or opportunity? [1]

Nature Reviews Drug Discovery

Volumn 5, Issue 9, 2006, Pages

  Au Yeung, Steve C F ^a   Pang, Patrick S K ^a,b   Ho, Yee Ping ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANTHARIDIN; CISPLATIN; NORCANTHARIDIN; OXALIPLATIN; PLATINUM COMPLEX; PLATINUM DERIVATIVE;

CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FLOW CYTOMETRY; LD 50; LETTER; PRIORITY JOURNAL;

EID: 33748297598     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1691-c1     Document Type: Letter

References (10)

1. Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nature Rev. Drug Discov. 4, 307-320 (2005).
2. Ho, Y.P. et al. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety, J. Med. Chem. 44, 2065 (2001)
3. McCluskey, A., Sim, T. R. & Sakoff, J. A. Serine-threonine protein phosphatase inhibitors: Development of potential therapeutic strategies, J. Med. Chem. 45, 1151 (2002).
4. Au-Yeung, S. C. F. et al. US patent No. 6,110,907 (2000).
5. Yu, C. W. et al. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg. Med. Chem. Lett. 16, 1686 (2006).
6. Sakoff, J. A. et al. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Investig. New Drugs 20, 1 (2002).
7. Kok, S. H. et al. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncology 39, 19 (2003).
8. Efferth, T. et al. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol. 69, 811 (2005).
9. Peng, F. et al. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: Involvement of the CD95 receptor/ ligand. Journal of Cancer Research and Clinical Oncology 128, 223 (2002).
10. Massicot, F. et al. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. Basic Clin. Pharmacol. and Toxicol. 96, 26 (2005).